Pharmafile Logo

Does Rare Disease Education Work?

December 23, 2025 |  

For a child with a rare disease, a doctor’s continuing education can end a years-long diagnostic odyssey and unlock access to vital care.

A harmful adage in diagnosis

In medical school, doctors are taught, ‘When you hear hoofbeats, think horses, not zebras,’ guiding them to focus on diagnosing common conditions and discard the possibility of a rare condition. Yet, approximately 5% of the global population does have a rare condition, which, collectively, isn’t rare.1 These patients experience an average diagnostic delay of four to five years, and depending on the condition, sometimes over 10 years.

Continuous learning for physicians

Most rare diseases are genetic and ~70% present in paediatrics, but paediatricians are regularly missing these cases.2 Unfortunately, very little time, if any, is dedicated to learning about rare diseases in medical school. Thus, for doctors to unlearn that potentially harmful adage about horses and zebras, they must learn about rare diseases by participating in continuing medical education throughout their careers.

‘When should I re-investigate a possible misdiagnosis?’ ‘What signs should make me think it might be a rare condition?’ These are the questions continuing medical education strives to answer.

Does rare disease education work?

Medscape Education features the largest collection of online continuing medical education programmes in rare disease, teaching about over 100 different rare conditions as well as rare disease foundations, patient voices and case challenges.

To evaluate the impact of education on real-world practice, we asked whether paediatricians who participated in rare disease education versus those who didn’t were more likely to order genetic tests (assessed via 30 relevant procedural codes). Analysing recent Medscape internal data from 24 paediatrics-geared programmes, we found that among paediatricians who ordered genetic tests, those who participated in rare disease education (n = 100) ordered them significantly more commonly than those who didn’t participate (n = 341).

Those who participated ordered genetic tests for an average of 9.63 patients versus an average of 5.70 patients among those who didn’t participate, representing 69% more patients per educated paediatrician who received a genetic test.

This has major implications for shortening the rare disease diagnostic delay in paediatric practice. If patients can get a diagnosis as early as possible, preferably as a child, as a result of better-informed doctors, we can end the frustrating diagnostic odyssey and enable earlier access to appropriate care.

- PMLiVE

Sources:

2. Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165-173. http://doi.org/10.1038/s41431-019-0508-0
1. Rohani-Montez SC, Bomberger J, Zhang C, et al. Educational needs in diagnosing rare diseases: A multinational, multispecialty clinician survey. Genet Med Open. 2023 Apr 17;1(1):100808. doi: 10.1016/j.gimo.2023.100808

 

For more information, please contact Christy Rohani Montez PHD –
srohani@medscape.net

About Medscape Education

Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

Exceptional Impact Presented at ECCMID 2024

The ECCMID conference in Barcelona, Spain marked the start of Medscape’s publication season in Europe. With three posters being presented at the conference, Medscape shared highlights from the powerful impact...

Showing Deep Expertise at ONS

The Medscape Oncology team will be connecting with the oncology nursing community this week in Washington, DC for the ONS Congress 2024.  Medscape Oncology has deep expertise in the oncology...

MEDSCAPE’S NEW AGE OF CERTAINTY FOR CME

The CME industry is changing. More than ever, activities need to be prioritized and measured to increase their impact on patient outcomes. Improving patient outcomes is the core objective for...

Getting Past the Old-Fashioned View of Patient Advocacy

Patient advocacy organizations today are data-driven, doing amazing work — and have the hard evidence to support their impact on patient care. The challenge is getting past the perception of...

Mile High Impact at AAN 2024

The Medscape team will be joining our neurology colleagues in Denver, CO for this year’s AAN Annual Meeting. Impact will take center stage at this year’s event as Medscape presents...

Everything Was Peachy at ACC 2024 in Atlanta, GA

The annual ACC meeting has officially wrapped up in Atlanta, bringing a successful conference to a close for another year.  During the conference, members of the Medscape team hosted a...

A Woman Should Not Be Treated As a Small Man

What should the future of women’s healthcare look like? Two renowned physicians say it involves a multidisciplinary, holistic approach, where a group of different specialists work together to provide a...

Sharing Four Times the Impact at ACC 2024

ACC is kicking off next week in Atlanta, GA, and Medscape is heading south to join our cardiology colleagues. The Medscape team will be hosting booth #3431 on the exhibit...

Transforming San Diego for AAD 2024

The 2024 meeting of the American Academy of Dermatology has wrapped up, and Medscape has returned from a series of successful days at their booth, symposia, and offsite event. To...

The Power Dynamics of Women and Cancer

Women, Power, and Cancer: a Lancet commission, studied the interaction of women and cancer through a social justice and equity lens. What does ‘power’ mean when it comes to cancer...